DLH Appoints Chief Scientist
DLH Holdings Corp. (NASDAQ: DLHC) announced the appointment of Sandra Halverson, MPH, PhD, as Chief Scientist effective November 1, 2020. Dr. Halverson, previously Director of the Survey Operations Center, will work with the Executive Leadership Team to shape research priorities and represent the company publicly within the health and life sciences sectors. Her background includes a PhD in Epidemiology and experience as Project Director for the NIEHS Sister Study. The leadership believes her skills will enhance DLH's competitive position amid current public health challenges.
- Sandra Halverson's appointment as Chief Scientist brings extensive experience and a strong academic background in epidemiology.
- Her leadership is expected to strengthen DLH's position in the public health and life sciences market.
- None.
ATLANTA, Nov. 05, 2020 (GLOBE NEWSWIRE) -- DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of innovative healthcare research, services and solutions to the federal government, today announced Sandra Halverson, MPH, PhD has been appointed Chief Scientist effective November 1, 2020. In this role, Dr. Halverson will work collaboratively with the DLH Executive Leadership Team to help set company research and scientific priorities. In addition to research coordination and personnel management duties, Sandra will serve as a public representative of the company, helping tell the story of DLH’s increasingly prominent role in the public health and life sciences market space.
Dr. Halverson currently serves as Director of DLH’s Survey Operations Center and as Project Director for the DLH-supported NIEHS Sister Study, a landmark research effort dedicated to finding the causes of breast cancer.
“We are thrilled that Sandra is taking on this larger role within DLH,” said Jeanine Christian, President of DLH’s Public Health and Scientific Research operating unit. “Her combination of discipline-specific knowledge, leadership skills, and business know-how will strengthen the competitive position of our company and ensure DLH is at the forefront of the latest scientific and technological advances.”
Dr. Halverson joined DLH in 2012 from her tenure-tracked position as Assistant Professor of Medicine at Vanderbilt University; she served as the Associate Director of Graduate Studies for the school’s Institute for Medicine and Public Health doctoral program in epidemiology. Sandra holds a PhD in Epidemiology from the University of North Carolina, Chapel Hill, as well as a Master of Public Health in Epidemiology and Biostatistics from The George Washington University School of Public Health and Health Services.
“This appointment will help build upon DLH’s position in the Public Health & Life Sciences market area,” said DLH President and CEO, Zach Parker. "In this time of public health crisis, our solutions in epidemiology, clinical trials, biomedical & environmental research including longitudinal studies, health policy analytics, and program evaluation are more vital than ever.”
About DLH
DLH (NASDAQ: DLHC) serves federal government clients throughout the United States and abroad delivering technology enabled solutions in key health and human services programs. The Company's core competencies include secure data analytics, clinical trials and laboratory services, case management, performance evaluation, system modernization, operational logistics and readiness, and strategic digital communications. DLH has approximately 2,000 employees serving numerous government agencies. For more information, visit the corporate website at www.dlhcorp.com
CONTACTS:
INVESTOR RELATIONS
Contact: Chris Witty
Phone: 646-438-9385
Email: cwitty@darrowir.com
FAQ
Who is the newly appointed Chief Scientist at DLHC?
What are Dr. Halverson's credentials?
What is DLH's focus following Dr. Halverson's appointment?
When did Sandra Halverson assume her role as Chief Scientist?
